About biohaven ltd - BHVN
Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.
BHVN At a Glance
Biohaven Ltd.
215 Church Street
New Haven, Connecticut 06510
| Phone | 1-203-404-0410 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -738,822,000.00 | |
| Sector | Health Technology | Employees | 274 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
BHVN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 28.788 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.592 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.241 |
BHVN Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,696,430.657 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
BHVN Liquidity
| Current Ratio | 3.177 |
| Quick Ratio | 3.177 |
| Cash Ratio | 2.759 |
BHVN Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -138.544 |
| Return on Equity | -310.751 |
| Return on Total Capital | -219.439 |
| Return on Invested Capital | -187.721 |
BHVN Capital Structure
| Total Debt to Total Equity | 546.578 |
| Total Debt to Total Capital | 84.534 |
| Total Debt to Total Assets | 63.045 |
| Long-Term Debt to Equity | 535.524 |
| Long-Term Debt to Total Capital | 82.824 |